Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Zions Bancorporation: A Stock Poised for Growth?

Andreas Sommer by Andreas Sommer
November 28, 2025
in Analysis, Banking & Insurance, Earnings
0
Zions Bancorporation NA Stock
0
SHARES
33
VIEWS
Share on FacebookShare on Twitter

Zions Bancorporation (ZION) finds itself at a compelling crossroads, navigating a landscape marked by significant institutional investment, an improved credit outlook, and quarterly results that present both strengths and challenges. Currently trading at $53.23, the bank boasts a market capitalization of $7.86 billion.

A Vote of Confidence from Major Investors

Institutional investors are demonstrating strong belief in Zions’ prospects. The second quarter saw substantial activity, with Carlson Capital acquiring 10,800 shares valued at $561,000. An even more significant move came from Prudential Financial, which boosted its position by 15%, adding 39,154 shares to bring its total investment to nearly $16 million. This activity has helped push the total institutional ownership to a notable 76.84%.

Credit Rating Shift to Stable

A key development occurred on November 19th, when S&P Global revised its outlook on Zions from “negative” to “stable,” while simultaneously affirming its BBB+ credit rating. This upgrade underscores the company’s fortified financial position, supported by several key metrics:

  • A solid CET1 capital ratio of 11.3%
  • A Tangible Common Equity ratio that has increased to 6.5%
  • A low level of problem loans, with a non-performing assets ratio of just 0.54%
  • A reduced reliance on brokered deposits, now down to 7.5% of the total

Quarterly Performance: A Tale of Two Quarters

The bank’s recent earnings reports reveal a story of contrasting quarters. Q2 was a period of record performance, driven by a net income of $243 million, translating to earnings per share of $1.63. Net interest income saw a healthy 9% increase to $648 million, and the net interest margin expanded to 3.17%.

Should investors sell immediately? Or is it worth buying Zions Bancorporation NA?

The subsequent third quarter presented a more mixed picture. While pre-provision net revenue grew by 14% and the net interest margin (NIM) improved further to 3.28%, the bank faced headwinds. Total loans declined by 3%, and it had to take a $50 million provision for credit losses tied to two specific commercial loans in California.

Consistent Returns for Shareholders

Amid these operational fluctuations, Zions has maintained its commitment to shareholder returns. The company continues its reliable dividend policy, with a recent quarterly payout of $0.45 per share offering an attractive dividend yield of 3.4%. This payment marks the 13th consecutive year of dividend increases, signaling a long-term commitment to returning value to investors.

Despite these positive indicators, market analysts maintain a cautious stance. The consensus rating currently sits at “Hold,” with an average price target of $61.29. This suggests a potential 15% upside from current levels, but experts appear to be waiting for more consistently positive operational signals before turning more bullish.

Ad

Zions Bancorporation NA Stock: Buy or Sell?! New Zions Bancorporation NA Analysis from February 7 delivers the answer:

The latest Zions Bancorporation NA figures speak for themselves: Urgent action needed for Zions Bancorporation NA investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Zions Bancorporation NA: Buy or sell? Read more here...

Tags: Zions Bancorporation NA
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026
CrossFirst Bankshares Stock
Analysis

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Myers Industries Stock
Analysis

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
Next Post
Quantum eMotion Stock

Quantum eMotion Stock Surges on AI Partnership Speculation

CBL & Associates Properties Stock

CBL Properties Faces Critical Holiday Season Test

Fluidigm Stock

Significant Insider Buying Sparks Rally in Standard BioTools Shares

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com